Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Allergan : Allergans Botox gets US FDA green light to treat forehead lines

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 04:15pm CEST

Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.

The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow`s feet" and glabellar lines.

In a statement released today announcing the FDA approval, David Nicholson, the companys chief research and development officer said: Allergan recognizes that forehead lines are a top area of concern for patients.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
10/19 ALLERGAN : Academy of Managed Care Pharmacy AMCP Foundation and Allergan Offered..
10/19 ALLERGAN : Announces that the FDA Accepts New Drug Application for Ulipristal Ac..
10/19 ALLERGAN : Announces Settlement on RESTASIS® Cyclosporine Ophthalmic Emulsion 0...
10/19 ALLERGAN : to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical..
10/19 SYNDAX PHARMACEUTICALS : Expands Pipeline with Exclusive Worldwide License to Al..
10/19 ALLERGAN : Issues Investor FAQ on Federal District Court RESTASIS® Patent Decisi..
10/18 ALLERGAN : ruling casts doubt on tribal patent strategy
10/18 ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
10/18 ALLERGAN : U.S. District Court for the Eastern District of Texas Issues Adverse ..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
More news
News from SeekingAlpha
10/20 Allergan Brings The Roof Down On Its Head
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 ALLERGAN'S FROWN LINES DEEPEN : Time To Reevaluate Management
10/20 Imprimis To Challenge Allergan's Restasis With Cheaper Product
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 984 M
Debt 2017 24 537 M
Yield 2017 1,55%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,50x
EV / Sales 2018 5,24x
Capitalization 62 943 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 241 $
Spread / Average Target 28%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-10.89%62 943
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116